These properties of IFN-γ are attractive for developing immunotherapies against cancer and infectious diseases, but systemic IFN-γ administration is ineffective due to rapid clearance and acute toxicity to healthy tissue (Rauch et al., 2013). The gene discussed is IFNG; the disease is cancer.